Business Trends– category –
-
Merck Ups 2026 Guidance on Strong Q2, KEYTRUDA Bladder Cancer Expansion, and ENFLONSIA RSV Indication Broadening Bolstering Investment Story
Simply Wall St USA Overview Merck achieved robust Q2 2026 performance and subsequently upgraded its full-year guidance, driven by key regulatory advancements. The company's investment narrative is significantly strengthened by the new bl... -
C4 Therapeutics Grants Stock Options to New Employees Under Nasdaq Rule, Bolstering TPD Talent Acquisition
C4 Therapeutics, Inc. USA Overview C4 Therapeutics (C4T) announced it has granted stock options to newly hired employees under Nasdaq Listing Rule 5635(c)(4). This inducement grant is a critical component of the company's strategy to adv... -
C4 Therapeutics Enters New Partnership with Roche for Degrader-Antibody Conjugate (DAC) Development, Reports Strong Q2
C4 Therapeutics, Inc. USA Overview C4 Therapeutics (C4T) reported robust financial results for Q2 2026 and announced a new collaboration agreement with Roche to advance research into degrader-antibody conjugate (DAC) modalities. This str... -
Merck’s sBLA for ENFLONSIA™ Accepted by FDA for Expanded RSV Prophylaxis in High-Risk Infants Under Two for Second Season
Merck.com (News releases) USA Overview Merck announced that the U.S. FDA has accepted its supplemental Biologics License Application (sBLA) for ENFLONSIA™ (clesrovimab-cfor) to expand its Respiratory Syncytial Virus (RSV) lower respirato... -
Exosome Therapeutics Advancing in Neurodegenerative and Oncology Fields, Eyeing Blood-Brain Barrier Penetration
BioInformant Global Overview Exosome therapeutics are showing significant promise in 2026, particularly for neurodegenerative diseases due to their unique ability to cross the blood-brain barrier, with clinical development also progressi... -
Gilead Report Highlights RNA Therapeutic Progress: GSK/Ionis HBV ASO Shows Positive Phase 3, Novartis FSHD siRNA Promising Early Data
The Bio Report USA Overview A Gilead report underscores significant advancements in RNA therapeutic clinical trials, with GSK/Ionis's beoprovirsen, an ASO targeting HBV, demonstrating positive Phase 3 results. Novartis's siRNA therapy, D... -
SynaptixBio Accelerates Regulatory Pathway for Ultra-Rare ASO Drugs, Expanding Therapeutic Potential of TUBB4A Mutant Silencers
Advancing RNA USA Overview SynaptixBio is effectively navigating the regulatory landscape for ultra-rare antisense oligonucleotide (ASO) drugs, securing Orphan Drug and Rare Pediatric Disease designations in collaboration with the FDA, E... -
FDA Approves Dawnzera: RNA-Targeting ASO Marks Paradigm Shift for Hereditary Angioedema
Liv Hospital Turkey Overview In August 2025, the FDA granted approval to Dawnzera (donidalorsen-azyh), a groundbreaking RNA-targeting antisense oligonucleotide (ASO) for hereditary angioedema (HAE). By specifically silencing prekallikrei... -
Dual-Targeting Lipid Nanoparticles Drastically Enhance β Cell-Specific RNA Delivery, Promising for Type 1 Diabetes Therapy
ACS Publications USA Overview Researchers have developed a dual-targeting lipid nanoparticle (LNP) engineering strategy that significantly enhances β cell-directed RNA delivery. This novel LNP demonstrated substantially improved in vivo ... -
QuantumScape Reports Progress on “Eagle Line” for Scalable Pilot Production of High-Energy-Density QSE-5 All-Solid-State Batteries, Accelerating EV Commercialization
Nasdaq / TradingView USA Overview QuantumScape has reported significant progress on its "Eagle Line," a highly automated pilot production line designed to demonstrate scalable manufacturing of its high-energy-density QSE-5 all-solid-stat...
